Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.
Adenocarcinoma
/ immunology
Aged
B7-H1 Antigen
/ analysis
Down-Regulation
Esophageal Neoplasms
/ immunology
Female
HLA-A Antigens
/ analysis
HLA-B Antigens
/ analysis
Humans
Immunity, Cellular
Inflammation
/ immunology
Lymphocyte Count
Lymphocytes, Tumor-Infiltrating
/ cytology
Male
Middle Aged
Neoplasm Invasiveness
/ immunology
Prognosis
Time Factors
Tumor Escape
/ immunology
Tumor Microenvironment
/ immunology
Adenocarcinoma of the esophagus
Computer applications software
Inflammation
MHC1
PD-L1
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
02
12
2020
accepted:
15
01
2021
pubmed:
11
2
2021
medline:
1
12
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
The inflammatory microenvironment has emerged as one of the focuses of cancer research. Little is known about the immune environment in esophageal adenocarcinoma (EAC) and possible tumor-escape mechanisms to avoid immune cell attack. We measured T cell inflammation (CD3, CD8) in the microenvironment using a standardized software-based evaluation algorithm considering different predefined tumor areas as well as expression of MHC class 1 and PD-L1 on 75 analyzable primarily resected and locally advanced (≥ pT2) EACs. We correlated these findings statistically with clinical data. Patients with high amounts of T cell infiltration in their tumor center showed a significant survival benefit of 41.4 months compared to 16.3 months in T cell poor tumors (p = 0.025), although CD3 fails to serve as an independent prognostic marker in multivariate analysis. For the invasion zone, a correlation between number of T-cells and overall survival was not detectable. Loss of MHC1 protein expression on tumor cells was seen in 32% and PD-L1 expression using the combined positive score (CPS) in 21.2%. Most likely due to small numbers of cases, both markers are not prognostically relevant, even though PD-L1 expression correlates with advanced tumor stages. Our analyses reveal an outstanding, though not statistically independent, prognostic relevance of T-cell-rich inflammation in our group of EACs, in particular driven by the tumor center. For the first time, we describe that the inner part of the invasion zone in EACs shows significantly fewer T-cells than other tumor segments and is prognostically irrelevant. We also demonstrate that the loss of antigen presenting ability via MHC1 downregulation by the carcinoma cells is a common escape mechanism in EACs. Future work will need to show whether tumors with MHC class 1 loss respond less well to immunotherapy.
Identifiants
pubmed: 33566304
doi: 10.1007/s12094-021-02556-2
pii: 10.1007/s12094-021-02556-2
pmc: PMC8238763
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
HLA-A Antigens
0
HLA-B Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1601-1610Investigateurs
H Loeser
(H)
T Zander
(T)
F Gebauer
(F)
A Quaas
(A)
Références
Eur J Surg Oncol. 2010 Jul;36(7):670-7
pubmed: 20510571
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Br J Cancer. 2015 Dec 22;113(12):1746
pubmed: 26695557
World J Gastrointest Oncol. 2017 Jul 15;9(7):293-299
pubmed: 28808502
Ann Surg. 2007 Feb;245(2):241-6
pubmed: 17245177
Cancer Immunol Immunother. 2016 Jun;65(6):651-62
pubmed: 27020682
Cancer Res. 2007 Mar 1;67(5):1883-6
pubmed: 17332313
CA Cancer J Clin. 2013 Jul-Aug;63(4):232-48
pubmed: 23818335
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Clin Cancer Res. 2004 Aug 1;10(15):5094-100
pubmed: 15297412
Immunol Today. 1997 Feb;18(2):89-95
pubmed: 9057360
N Engl J Med. 2019 Jan 10;380(2):152-162
pubmed: 30625052
Oncoimmunology. 2017 Feb 23;6(3):e1286436
pubmed: 28405518
Eur J Cancer. 2018 May;94:104-114
pubmed: 29550565
Cancer Prev Res (Phila). 2016 Nov;9(11):828-834
pubmed: 27623934
Sci Rep. 2018 Sep 5;8(1):13281
pubmed: 30185893
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
Oncoimmunology. 2018 Mar 13;7(6):e1435226
pubmed: 29872575
Virchows Arch. 2020 Dec;477(6):825-834
pubmed: 32533341
Cancer Epidemiol. 2012 Dec;36(6):505-12
pubmed: 22910036
Oncologist. 2018 Nov;23(11):1319-1327
pubmed: 29866946
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Genome Med. 2018 Nov 29;10(1):93
pubmed: 30497521
Br J Cancer. 2014 Mar 18;110(6):1595-605
pubmed: 24504370
Pathology. 2017 Jan;49(1):30-37
pubmed: 27916317
Nature. 2017 Jan 12;541(7636):169-175
pubmed: 28052061
BMC Cancer. 2010 Nov 05;10:608
pubmed: 21054833
Cancer Res. 2001 May 15;61(10):3932-6
pubmed: 11358808
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
Eur J Cancer. 2014 Jan;50(2):309-19
pubmed: 24103145
Ann Surg. 2015 Nov;262(5):817-22; discussion 822-3
pubmed: 26583671
J Gastroenterol Hepatol. 2016 Jun;31(6):1141-6
pubmed: 26749521
World J Surg. 2010 Apr;34(4):738-43
pubmed: 20098986
Gut. 2013 Oct;62(10):1406-14
pubmed: 22917659
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Int J Cancer. 1997 Apr 10;71(2):142-7
pubmed: 9139833
Curr Top Microbiol Immunol. 2011;344:1-24
pubmed: 20512556
Cancer Immunol Immunother. 2017 Jun;66(6):777-786
pubmed: 28289861
Ann Thorac Surg. 2018 Oct;106(4):1002-1007
pubmed: 29859152